Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Key Points Question Are there differences in the magnitude and durability of neutralizing antibody (nAb) responses against SARS-CoV-2 variants of concern (VOCs) according to the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines? Findings In this comparative effectiveness study of 637 immunocompromised patients and 204 healthy control participants who received 2 doses of messenger RNA COVID-19 vaccines, nAb responses against the Beta and Delta variants were short lived (3 to 7 months) compared with original, nonvariant SARS-CoV-2 and other variants. Higher nAb titers and longer durability of humoral responses were associated with vaccination with the mRNA-1273 vaccine. Meaning The faster disappearance of the nAb responses in certain groups of immunocompromised patients suggests that boosting vaccine strategies need to be personalized to the underlying disease.

[1]  A. Milstone,et al.  Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. , 2021, JAMA.

[2]  L. Abu-Raddad,et al.  Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. , 2021, JAMA.

[3]  R. Baric,et al.  Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.

[4]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[5]  C. Hirzel,et al.  Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study , 2021, The Lancet Rheumatology.

[6]  B. Mustanski,et al.  Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history , 2021, Scientific Reports.

[7]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[8]  M. Davids,et al.  Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies , 2021, Blood Advances.

[9]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma , 2021, Blood Advances.

[10]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[11]  S. Stemmer,et al.  Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment , 2021, JAMA oncology.

[12]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[13]  M. C. Muenker,et al.  Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity , 2021, Nature.

[14]  G. Pantaleo,et al.  A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma , 2021, Science Translational Medicine.

[15]  M. Brown,et al.  The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study , 2021, The Lancet Rheumatology.

[16]  A. Addeo,et al.  Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer , 2021, Cancer Cell.

[17]  D. Segev,et al.  Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.

[18]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia , 2021, Blood.

[19]  D. Montefiori,et al.  Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 , 2021, The New England journal of medicine.

[20]  T. Ndung’u,et al.  Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma , 2021, Nature.

[21]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[22]  H. Jäck,et al.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.

[23]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[24]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[25]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[26]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.

[27]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[28]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[29]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.

[30]  Nuno R. Faria,et al.  Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence , 2021, The Lancet.

[31]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[32]  G. Pantaleo,et al.  Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.

[33]  D. Micic,et al.  Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis , 2020, Annals of the Rheumatic Diseases.

[34]  M. Ison,et al.  COVID-19 in solid organ transplant: A multi-center cohort study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Zelenetz,et al.  Outcomes of COVID-19 in patients with CLL: a multicenter international experience , 2020, Blood.

[36]  E. Montserrat,et al.  COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus , 2020, Leukemia.

[37]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[38]  David Atkins,et al.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .